STOCK TITAN

[SCHEDULE 13G/A] EyePoint Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 6,800,000 shares of EyePoint Pharmaceuticals common stock, representing 9.88% of the company based on 68,811,736 shares outstanding. The filing states the reporting persons hold shared voting and shared dispositive power over the shares and report no sole voting or dispositive power. Adage is identified as the investment manager of the entity that directly holds the shares. The reporting persons certify these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Adage Capital Management, L.P., insieme a Robert Atchinson e Phillip Gross, dichiara la proprietà effettiva di 6,800,000 azioni ordinarie di EyePoint Pharmaceuticals, pari al 9.88% della società sulla base di 68,811,736 azioni in circolazione. La comunicazione afferma che le persone segnalanti detengono potere di voto condiviso e potere di disposizione condiviso sulle azioni e dichiarano di non avere alcun potere di voto o di disposizione esclusivo. Adage è indicata come il gestore degli investimenti dell'entità che detiene direttamente le azioni. Le persone segnalanti certificano che questi titoli sono detenuti nell'ordinario corso dell'attività e non allo scopo di modificare o influenzare il controllo dell'emittente.

Adage Capital Management, L.P., junto con Robert Atchinson y Phillip Gross, declara la propiedad beneficiaria de 6,800,000 acciones ordinarias de EyePoint Pharmaceuticals, que representan el 9.88% de la compañía sobre 68,811,736 acciones en circulación. La presentación indica que las personas informantes ostentan poder de voto compartido y poder de disposición compartido sobre las acciones y que no tienen ningún poder de voto o de disposición exclusivo. Adage figura como gestor de inversiones de la entidad que posee directamente las acciones. Las personas informantes certifican que estos valores se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor.

Adage Capital Management, L.P.는 Robert Atchinson 및 Phillip Gross와 함께 EyePoint Pharmaceuticals의 보통주 6,800,000주에 대한 실소유권을 보유하고 있으며, 이는 총 68,811,736주를 기준으로 회사의 9.88%에 해당한다고 보고합니다. 제출서류는 보고 당사자들이 해당 주식에 대해 공동 의결권 및 공동 처분권을 보유하고 있으며 단독 의결권 또는 단독 처분권은 없음을 보고한다고 명시합니다. Adage는 주식을 직접 보유한 기관의 투자 매니저로 지정되어 있습니다. 보고 당사자들은 이 증권이 통상적인 영업 범위 내에서 보유되고 있으며 발행인의 지배권을 변경하거나 영향을 미칠 목적으로 보유된 것이 아님을 증명합니다.

Adage Capital Management, L.P., conjointement avec Robert Atchinson et Phillip Gross, déclare détenir la propriété bénéficiaire de 6,800,000 actions ordinaires d'EyePoint Pharmaceuticals, représentant 9.88% de la société sur la base de 68,811,736 actions en circulation. Le dépôt indique que les déclarants détiennent le pouvoir de vote conjoint et le pouvoir dispositif conjoint sur ces actions et déclarent ne pas détenir de pouvoir de vote ou de disposition exclusif. Adage est identifié comme le gestionnaire d'investissement de l'entité qui détient directement les actions. Les déclarants certifient que ces titres sont détenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur.

Adage Capital Management, L.P., zusammen mit Robert Atchinson und Phillip Gross, meldet eine wirtschaftliche Eigentümerschaft von 6,800,000 Aktien der Stammaktien von EyePoint Pharmaceuticals, was 9.88% des Unternehmens auf Basis von 68,811,736 ausstehenden Aktien entspricht. Die Meldung besagt, dass die berichtenden Personen gemeinsames Stimm- und gemeinsames Verfügungsrecht über die Aktien ausüben und kein alleiniges Stimm- oder Verfügungsrecht besitzen. Adage wird als Investmentmanager der Einheit identifiziert, die die Aktien direkt hält. Die berichtenden Personen bestätigen, dass diese Wertpapiere im normalen Geschäftsverlauf gehalten werden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle des Emittenten.

Positive
  • Material disclosure of ownership: 6,800,000 shares representing 9.88% of the outstanding common stock
  • Holdings certified as held in the ordinary course of business and not acquired to change or influence control
Negative
  • No sole voting or dispositive power reported; all authority is shared, limiting direct unilateral influence

Insights

TL;DR: A material, passive stake of 6.8M shares (9.88%) is disclosed, held with shared voting/dispositive power and stated as not intended to influence control.

This Schedule 13G/A discloses a meaningful equity position that meets the >5% materiality threshold, which may attract investor attention given its size relative to the 68.8M share base. The position is reported as passive: shared voting and dispositive authority are noted and the filer certifies ordinary-course intent, which reduces immediate governance implications. For market impact, the disclosure increases transparency about significant holders but does not alone indicate activist intent or control changes.

TL;DR: Reporting persons hold substantial but non-controlling, shared authority and explicitly state no intent to influence corporate control.

The filing identifies Adage as investment manager of the holder and shows that Robert Atchinson and Phillip Gross share voting and dispositive power over 6.8M shares, with no sole authority. The explicit certification that the stake is held in the ordinary course and not to effect control is material for governance assessment: it signals passive ownership under applicable rules and limits immediate governance escalation. Continued monitoring of any future amendments or Schedule 13D filings is warranted.

Adage Capital Management, L.P., insieme a Robert Atchinson e Phillip Gross, dichiara la proprietà effettiva di 6,800,000 azioni ordinarie di EyePoint Pharmaceuticals, pari al 9.88% della società sulla base di 68,811,736 azioni in circolazione. La comunicazione afferma che le persone segnalanti detengono potere di voto condiviso e potere di disposizione condiviso sulle azioni e dichiarano di non avere alcun potere di voto o di disposizione esclusivo. Adage è indicata come il gestore degli investimenti dell'entità che detiene direttamente le azioni. Le persone segnalanti certificano che questi titoli sono detenuti nell'ordinario corso dell'attività e non allo scopo di modificare o influenzare il controllo dell'emittente.

Adage Capital Management, L.P., junto con Robert Atchinson y Phillip Gross, declara la propiedad beneficiaria de 6,800,000 acciones ordinarias de EyePoint Pharmaceuticals, que representan el 9.88% de la compañía sobre 68,811,736 acciones en circulación. La presentación indica que las personas informantes ostentan poder de voto compartido y poder de disposición compartido sobre las acciones y que no tienen ningún poder de voto o de disposición exclusivo. Adage figura como gestor de inversiones de la entidad que posee directamente las acciones. Las personas informantes certifican que estos valores se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor.

Adage Capital Management, L.P.는 Robert Atchinson 및 Phillip Gross와 함께 EyePoint Pharmaceuticals의 보통주 6,800,000주에 대한 실소유권을 보유하고 있으며, 이는 총 68,811,736주를 기준으로 회사의 9.88%에 해당한다고 보고합니다. 제출서류는 보고 당사자들이 해당 주식에 대해 공동 의결권 및 공동 처분권을 보유하고 있으며 단독 의결권 또는 단독 처분권은 없음을 보고한다고 명시합니다. Adage는 주식을 직접 보유한 기관의 투자 매니저로 지정되어 있습니다. 보고 당사자들은 이 증권이 통상적인 영업 범위 내에서 보유되고 있으며 발행인의 지배권을 변경하거나 영향을 미칠 목적으로 보유된 것이 아님을 증명합니다.

Adage Capital Management, L.P., conjointement avec Robert Atchinson et Phillip Gross, déclare détenir la propriété bénéficiaire de 6,800,000 actions ordinaires d'EyePoint Pharmaceuticals, représentant 9.88% de la société sur la base de 68,811,736 actions en circulation. Le dépôt indique que les déclarants détiennent le pouvoir de vote conjoint et le pouvoir dispositif conjoint sur ces actions et déclarent ne pas détenir de pouvoir de vote ou de disposition exclusif. Adage est identifié comme le gestionnaire d'investissement de l'entité qui détient directement les actions. Les déclarants certifient que ces titres sont détenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur.

Adage Capital Management, L.P., zusammen mit Robert Atchinson und Phillip Gross, meldet eine wirtschaftliche Eigentümerschaft von 6,800,000 Aktien der Stammaktien von EyePoint Pharmaceuticals, was 9.88% des Unternehmens auf Basis von 68,811,736 ausstehenden Aktien entspricht. Die Meldung besagt, dass die berichtenden Personen gemeinsames Stimm- und gemeinsames Verfügungsrecht über die Aktien ausüben und kein alleiniges Stimm- oder Verfügungsrecht besitzen. Adage wird als Investmentmanager der Einheit identifiziert, die die Aktien direkt hält. Die berichtenden Personen bestätigen, dass diese Wertpapiere im normalen Geschäftsverlauf gehalten werden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle des Emittenten.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2025

FAQ

How many EyePoint (EYPT) shares does Adage report owning?

The filing reports 6,800,000 shares of EyePoint common stock as beneficially owned by the reporting persons.

What percentage of EYPT does the 6,800,000-share position represent?

The 6,800,000-share position represents 9.88% of the class based on an aggregate of 68,811,736 shares outstanding referenced in the filing.

Do the reporting persons have sole voting or dispositive power over the EYPT shares?

No. The filing states 0 sole voting power and 0 sole dispositive power, and records shared voting and shared dispositive power of 6,800,000 shares.

Who are the reporting persons listed in the Schedule 13G/A for EYPT?

The reporting persons are Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross.

Is the disclosed stake described as passive or active?

The filing includes a certification that the securities are acquired and held in the ordinary course of business and not to change or influence control, indicating passive intent.
Eyepoint Pharmac

NASDAQ:EYPT

EYPT Rankings

EYPT Latest News

EYPT Latest SEC Filings

EYPT Stock Data

708.23M
63.49M
3.52%
110.46%
9.76%
Biotechnology
Laboratory Analytical Instruments
Link
United States
WATERTOWN